Reata Pharmaceuticals (RETA) Reports Q2 Loss of $0.05/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Reata Pharmaceuticals (RETA) Reports Q2 Loss of $0.05/Share

Reata Pharmaceuticals, Inc. Announces Second Quarter 2016 Financial and Operating Results

August 11, 2016 5:00 PM EDT

IRVING, Texas, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata or the Company), a clinical stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016 and provided an update on the Company's business and product development programs.

Financial Highlights

The Company incurred operating expenses of $13.8 million for the quarter ended June 30, 2016, with research and development accounting for $9.1 million. This compares to operating expenses of $13.6 million for the same period of the year prior, with research and development accounting for... More